JP2005501548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005501548A5 JP2005501548A5 JP2003525297A JP2003525297A JP2005501548A5 JP 2005501548 A5 JP2005501548 A5 JP 2005501548A5 JP 2003525297 A JP2003525297 A JP 2003525297A JP 2003525297 A JP2003525297 A JP 2003525297A JP 2005501548 A5 JP2005501548 A5 JP 2005501548A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- enzyme
- protein
- cell
- cellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 131
- 108090000623 proteins and genes Proteins 0.000 claims description 91
- 108020001507 fusion proteins Proteins 0.000 claims description 86
- 102000037865 fusion proteins Human genes 0.000 claims description 81
- 102000004169 proteins and genes Human genes 0.000 claims description 62
- 102000004190 Enzymes Human genes 0.000 claims description 45
- 108090000790 Enzymes Proteins 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 37
- 230000015556 catabolic process Effects 0.000 claims description 31
- 230000001413 cellular effect Effects 0.000 claims description 31
- 238000006731 degradation reaction Methods 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 27
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 15
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 15
- 239000013598 vector Substances 0.000 claims description 14
- 239000006166 lysate Substances 0.000 claims description 11
- 230000027455 binding Effects 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000002103 transcriptional effect Effects 0.000 claims description 5
- 238000013519 translation Methods 0.000 claims description 5
- 239000013592 cell lysate Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 108091008768 PPARγ1 Proteins 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 description 49
- 235000018102 proteins Nutrition 0.000 description 44
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 230000037361 pathway Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 5
- 229960004484 carbachol Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000017925 CHRM3 Human genes 0.000 description 2
- 101150060249 CHRM3 gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000003174 enzyme fragment complementation Methods 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 230000004950 I-kappaB phosphorylation Effects 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100034574 P protein Human genes 0.000 description 1
- 101710181008 P protein Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 101710177166 Phosphoprotein Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 102000052708 Recessive Genes Human genes 0.000 description 1
- 108700005079 Recessive Genes Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000004640 cellular pathway Effects 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid esters Chemical group 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000006127 geranylation Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical group 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31642801P | 2001-08-30 | 2001-08-30 | |
| US60/316,428 | 2001-08-30 | ||
| US34315601P | 2001-10-21 | 2001-10-21 | |
| US60/343,156 | 2001-10-22 | ||
| US35308602P | 2002-01-30 | 2002-01-30 | |
| US60/353,086 | 2002-01-30 | ||
| PCT/US2002/027497 WO2003021265A1 (en) | 2001-08-30 | 2002-08-27 | Genetic construct intracellular monitoring system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005501548A JP2005501548A (ja) | 2005-01-20 |
| JP2005501548A5 true JP2005501548A5 (https=) | 2008-11-20 |
| JP5580505B2 JP5580505B2 (ja) | 2014-08-27 |
Family
ID=27405870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003525297A Expired - Lifetime JP5580505B2 (ja) | 2001-08-30 | 2002-08-27 | 遺伝子構築細胞モニターシステム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7479377B2 (https=) |
| EP (1) | EP1421385B1 (https=) |
| JP (1) | JP5580505B2 (https=) |
| AU (1) | AU2002332724A1 (https=) |
| CA (1) | CA2458879C (https=) |
| WO (1) | WO2003021265A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1582332A (zh) * | 2001-12-29 | 2005-02-16 | Seoul大学校产学协力财团 | 转染gfp的克隆猪、敲除gt的克隆猪及其生产方法 |
| EP1556682B8 (en) * | 2002-10-21 | 2010-02-17 | DiscoveRx Corporation | Ip3 protein binding assay |
| JP2007521021A (ja) * | 2003-11-06 | 2007-08-02 | ディスカヴァーエックス インコーポレイテッド | 細胞膜タンパク質の検定 |
| US8586294B2 (en) * | 2004-05-18 | 2013-11-19 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of protein translocation by beta-galactosidase reporter fragment complementation |
| JP4796059B2 (ja) | 2004-06-30 | 2011-10-19 | ディスカヴァーエックス コーポレイション | 細胞内修飾の分析 |
| WO2007002200A2 (en) * | 2005-06-21 | 2007-01-04 | Discoverx, Inc. | Mitotic index assay |
| WO2009043953A1 (es) * | 2007-10-05 | 2009-04-09 | Proyecto De Biomedicina Cima, S.L. | Empleo de inhibidores de ppar alfa truncado en el tratamiento de la insuficiencia cardiaca en sujetos con cardiopatía hipertensiva |
| US8865421B2 (en) * | 2008-07-02 | 2014-10-21 | Discoverx Corporation | Assays for nuclear hormone receptor binding |
| US20100120063A1 (en) * | 2008-10-10 | 2010-05-13 | Discoverx Corporation | GPCR Arrestin Assays |
| US8211655B2 (en) * | 2009-02-12 | 2012-07-03 | Discoverx Corporation | Wild-type receptor assays |
| GB0905419D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Uk Ltd | Methods for testing ligand binding to G protein-coupled receptors |
| GB0917877D0 (en) | 2009-10-13 | 2009-11-25 | Ge Healthcare Uk Ltd | Enzyme fragment complementation assays for monitoring the activiation of the voltage-gated potassium ion channel herg |
| WO2013119579A1 (en) * | 2012-02-06 | 2013-08-15 | Discoveryx Corporation | Detection of intracellular binding events by measuring protein abundance |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604091A (en) * | 1984-03-01 | 1997-02-18 | Microgenics Corporation | Methods for protein binding enzyme complementation |
| US4708929A (en) * | 1984-10-29 | 1987-11-24 | Microgenics Corporation | Methods for protein binding enzyme complementation assays |
| DE69731960T2 (de) * | 1996-09-24 | 2005-12-15 | Cadus Pharmaceutical Corp. | Verfahren und zusammensetzungen für die identifizierung von receptor effectoren |
| US6037133A (en) * | 1998-04-17 | 2000-03-14 | Clontech Laboratories, Inc. | IκBEGFP constructs, cell lines and methods of use |
-
2002
- 2002-08-27 JP JP2003525297A patent/JP5580505B2/ja not_active Expired - Lifetime
- 2002-08-27 WO PCT/US2002/027497 patent/WO2003021265A1/en not_active Ceased
- 2002-08-27 CA CA2458879A patent/CA2458879C/en not_active Expired - Lifetime
- 2002-08-27 US US10/229,747 patent/US7479377B2/en not_active Expired - Lifetime
- 2002-08-27 AU AU2002332724A patent/AU2002332724A1/en not_active Abandoned
- 2002-08-27 EP EP02797782.6A patent/EP1421385B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12379384B2 (en) | Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity | |
| Salt et al. | AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the α2 isoform | |
| Woods et al. | Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 | |
| US5877007A (en) | Method of screening for protein inhibitors and activators | |
| Bai et al. | Markedly reduced activity of mutant calcium-sensing receptor with an inserted Alu element from a kindred with familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. | |
| Fujita et al. | Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex | |
| US5266464A (en) | Method of screening for protein inhibitors and activators | |
| Flanagan et al. | Alkaline phosphatase fusion proteins for molecular characterization and cloning of receptors and their ligands | |
| JP2005501548A5 (https=) | ||
| Sprenger et al. | Biochemical analysis of torso and D-raf during Drosophila embryogenesis: implications for terminal signal transduction | |
| JP2003501074A (ja) | 概日リズムタンパク質の変化に関するスクリーニング方法 | |
| JP5580505B2 (ja) | 遺伝子構築細胞モニターシステム | |
| JPWO2020050208A1 (ja) | Ｔｓｈ受容体に対する自己抗体活性の測定方法及びキット | |
| US7615380B2 (en) | Methods for modulating an immune response by modulating KRC activity | |
| HU220345B (hu) | Eljárás interleukin-5-receptorfüggő, celluláris jelátvivő útra moduláló hatással rendelkező anyagok kiszűrésére | |
| US20020015943A1 (en) | Assays, methods and means relating to the modulation of levels of nuclear beta-catenin | |
| KR101560849B1 (ko) | 자가면역 질환을 확인하기 위해 키메라 수용체를 사용하는 민감하고 신속한 방법 | |
| US20040137480A1 (en) | Monitoring intracellular proteins | |
| US7344833B2 (en) | Methods and compositions for modulating activator protein 1 | |
| EP1637540A1 (en) | Hyperactive Stat molecules and their use in assays employing gene activation | |
| JP2009513150A (ja) | シグナリングアッセイ及び株化細胞 | |
| US20050065081A1 (en) | Tyrosine kinase inhibitors | |
| JP2000354500A (ja) | Ｇ蛋白質共役型受容体リガンドのスクリーニング法並びにｇ蛋白質共役型受容体のエクスプレッションクローニング法 | |
| EP1143011B1 (en) | A method of detecting biologically active substances | |
| EP2020447A1 (en) | Method for identifying compounds modulating adiponectin gene expression |